News Articles http://www.pharmaceuticalonline.com/ Thu, 18 Mar 2010 12:56:53 GMT Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that it has entered into a definitive agreement to acquire ratiopharm, Germany's second largest generics producer and the sixth largest generic drug company worldwide, for an enterprise value of 3.625 billion. The transaction is subject to certain conditions including relevant regulatory approvals. http://www.pharmaceuticalonline.com/article.mvc/Teva-To-Acquire-Ratiopharm-0001?atc~c=771+s=773+r=001+l=a Thu, 18 Mar 2010 12:56:53 GMT American pharmaceutical manufacturer Alpharma Inc. has agreed to pay $42.5M to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug, Kadian, the Justice Department announced today. http://www.pharmaceuticalonline.com/article.mvc/Alpharma-To-Pay-425M-To-Resolve-False-0001?atc~c=771+s=773+r=001+l=a Thu, 18 Mar 2010 10:15:00 GMT UltraCap® H.D. (Heavy Duty) single-use high capacity capsule filters provide high flow rates and high throughput, in lengths up to 40 inches (100 cm) for large volume filtration. http://www.pharmaceuticalonline.com/article.mvc/UltraCap-HD-Capsule-in-40-inch-Length-0001?atc~c=771+s=773+r=001+l=a Thu, 18 Mar 2010 06:00:00 GMT Teva Pharmaceutical Industries Ltd., announced recently that the parties to the patent litigation regarding Barr's U.S. generic version of Schering's Temodar® have entered into an agreement pending resolution of Schering's appeal to the Federal Circuit of the U.S. District Court's decision holding the '291 Patent unenforceable. http://www.pharmaceuticalonline.com/article.mvc/Teva-Provides-Update-On-Generic-Temodar-0001?atc~c=771+s=773+r=001+l=a Wed, 17 Mar 2010 13:20:00 GMT Mannatech, Incorporated, a global pioneer in the development of high-quality health, weight and fitness and skin care solutions based on nutritional science, announced it has filed a complaint against seven independent companies for infringement on Mannatech's patents (U.S. Patents 6,929,807; 7,157,431; 7,199,104; and 7,202,220). http://www.pharmaceuticalonline.com/article.mvc/Mannatech-Vigorously-Defends-Ambrotose-0001?atc~c=771+s=773+r=001+l=a Wed, 17 Mar 2010 13:15:00 GMT Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). http://www.pharmaceuticalonline.com/article.mvc/Human-Genome-Sciences-Announces-Results-Of-Ra-0001?atc~c=771+s=773+r=001+l=a Wed, 17 Mar 2010 13:11:00 GMT Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam orally disintegrating tablets. Distribution of the product will commence immediately. http://www.pharmaceuticalonline.com/article.mvc/Actavis-Receives-Approval-of-Alprazolam-ODT-i-0001?atc~c=771+s=773+r=001+l=a Wed, 17 Mar 2010 12:39:00 GMT Alpharma Inc. has agreed to pay $42.5 million to the federal government and certain states to settle a whistleblower lawsuit that exposed an alleged kickback scheme by the pharmaceutical company to boost its sales of Kadian, a prescription painkiller. http://www.pharmaceuticalonline.com/article.mvc/Whistleblower-Kickback-Case-Against-Alpharma-0001?atc~c=771+s=773+r=001+l=a Wed, 17 Mar 2010 12:27:00 GMT Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, announced that its Access Knowledge Institute Courses for Biomanufacturing have been certified by the International Association for Continuing Education and Training (IACET) and authorized to grant continuing education credits. http://www.pharmaceuticalonline.com/article.mvc/Biomanufacturing-Courses-Receive-0001?atc~c=771+s=773+r=001+l=a Wed, 17 Mar 2010 07:31:00 GMT The Porvair Sciences Product Catalogue for 2010 is packed with vital information on the company's wide range of microplates, plate sealers and microplate evaporators to help you get the best from your separations, assays and storage applications. http://www.pharmaceuticalonline.com/article.mvc/Comprehensive-Microplate-Catalogue-0001?atc~c=771+s=773+r=001+l=a Wed, 17 Mar 2010 07:24:00 GMT Agilent Automation Solutions has announced a configuration of its BioCel System that allows laboratories to fully automate cell-based ELISA procedures thereby reducing the risk of human error, contamination and time spent on tedious manual procedures. http://www.pharmaceuticalonline.com/article.mvc/Accelerating-Cell-Based-ELISA-Procedures-0001?atc~c=771+s=773+r=001+l=a Wed, 17 Mar 2010 07:20:00 GMT BioTek's new Synergy H4 Hybrid Microplate Reader has received Transcreener approval from BellBrook Labs (Madison, WI). The approval extends to the Transcreener Fluorescence Polarization, Far Red, Red Fluorescence (FI) and Red TR-FRET assays, and means that the Synergy H4 meets strict standards in instrument setup and assay performance. http://www.pharmaceuticalonline.com/article.mvc/BioTeks-Synergy-H4-Hybrid-Reader-Is-0002?atc~c=771+s=773+r=001+l=a Wed, 17 Mar 2010 06:34:00 GMT The K-Tron Process Group is proud to introduce ActiFlow™ Smart Bulk Solids Activator, an innovative method to reliably prevent bridging and rat-holing of cohesive bulk materials in stainless steel hoppers without internal hopper agitation. http://www.pharmaceuticalonline.com/article.mvc/K-Tron-Process-Group-Introduces-A-New-0001?atc~c=771+s=773+r=001+l=a Wed, 17 Mar 2010 04:56:00 GMT ROTATEQ (Rotavirus Vaccine, Live, Oral, Pentavalent), the vaccine from Merck that helps prevent rotavirus gastroenteritis in infants and children, has received an extension of its prequalification status by the World Health Organization (WHO), to include its use in Asia and Africa. http://www.pharmaceuticalonline.com/article.mvc/WHO-Extends-Prequalification-Of-Mercks-0001?atc~c=771+s=773+r=001+l=a Tue, 16 Mar 2010 09:31:00 GMT Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON(TM) (exenatide for extended-release injectable suspension). http://www.pharmaceuticalonline.com/article.mvc/Amylin-Lilly-And-Alkermes-Receive-Complete-R-0001?atc~c=771+s=773+r=001+l=a Mon, 15 Mar 2010 20:40:00 GMT http://www.pharmaceuticalonline.com/article.mvc/FDA-Update-March-15-2010-0001?atc~c=771+s=773+r=001+l=a Mon, 15 Mar 2010 18:27:00 GMT Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets. http://www.pharmaceuticalonline.com/article.mvc/Ranbaxy-Announces-Settlement-Of-Actos-0001?atc~c=771+s=773+r=001+l=a Mon, 15 Mar 2010 18:23:00 GMT Sigma-Aldrich(R) (Nasdaq: SIAL) today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small molecule compounds to life science researchers for target characterization, assay development, screening and in vivo animal model applications. http://www.pharmaceuticalonline.com/article.mvc/Sigma-Aldrich-Reaches-Agreement-0001?atc~c=771+s=773+r=001+l=a Mon, 15 Mar 2010 18:17:16 GMT New York, (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced it has entered into a definitive agreement and plan of merger and completed the merger transaction with Ariston Pharmaceuticals, Inc., a privately-held, specialty pharmaceutical company. As a result of the merger, Ariston became a wholly owned subsidiary of Manhattan Pharmaceuticals. http://www.pharmaceuticalonline.com/article.mvc/Manhattan-Pharmaceuticals-Completes-Merger-0001?atc~c=771+s=773+r=001+l=a Mon, 15 Mar 2010 18:09:37 GMT Laxai Pharma, Ltd. (f/k/a NexGen Biofuels, Ltd.) (OTCBB:NXGNF) today announced that it has completed its first acquisition in the clinical research services space by purchasing all of the assets of OSR Solutions, Inc. ("OSR"), a New Jersey based contract research organization ("CRO"), for $3.6 million consisting of the following: $1.5mm in cash, $0.75mm in notes, $0.60mm in assumed liabilities, and 5.6mm common shares of Laxai Pharma, Ltd. -- about 10% of the issued and outstanding common shares at closing. The acquisition was financed by a combination of debt and equity. http://www.pharmaceuticalonline.com/article.mvc/Laxai-Pharma-Completes-Asset-Purchase-0001?atc~c=771+s=773+r=001+l=a Mon, 15 Mar 2010 18:04:00 GMT